<DOC>
	<DOCNO>NCT00159926</DOCNO>
	<brief_summary>Cardiac surgery use heart lung machine produce inflammatory reaction body . This lead percent case heart , lung , kidney disturbance potentially cause death . White blood cell contact heart lung machine external surface release mediator partly responsible . Blood collect suction blood remain heart lung machine use , clean cell saver reinfusion , might reduce inflammatory response .</brief_summary>
	<brief_title>Cleansing Suction Blood Cardiac Surgery Reduced Inflammatory Response</brief_title>
	<detailed_description>Introduction Cardiopulmonary bypass ( CPB ) cardiac surgery induce patient systemic inflammatory response syndrome ( SIRS ) pronounce surgical procedure . Depending severity , myocardial dysfunction , respiratory failure , renal neurological dysfunction , coagulation disturbance impair liver function might follow . In bad case lead acute respiratory distress syndrome , disseminate intravascular coagulation , multi organ failure , shock death . The cause besides surgical trauma , passage blood extra corporal circulation ( ECC ) pump oxygenator , hemodilution , hypothermia , heparin protamine administration , ischemia reperfusion , endotoxemia ( LPS ) cause intestinal ischemia . The ECC main cause immunological activation lead severe case so-called post-perfusion syndrome . This characterise increased capillary permeability intercellular fluid , peripheral vasoconstriction , fever , myocardial edema , diffuse cerebral edema diffuse hemorrhagic diathesis . This syndrome consider severe form SIRS . Even though patient sequelae CPB , patient must consider influenced , vary degree , SIRS . High level pro-inflammatory cytokine ( interleukin ( IL ) -6 , IL-8 , IL-1a , IL-1b , tumor necrosis factor ( TNF ) alfa ) , generally associate adverse event CPB . Of importance also LPS gram-negative intestinal bacteria , translocate systemic circulation ischemia . Hypothesis Cleansing suction blood remain blood ECC termination CPB , reduce load inflammatory cell mediator patient ' circulation . This potentially diminish SIRS reduction postoperative organ dysfunction morbidity . Aim To cleanse suction blood remain blood ECC termination CPB mean cell saver monitor influence inflammatory mediator potential clinical benefit . Outcome measure Primary : Concentrations IL-1B , IL-6 , IL-8 , IL-10 , IL-12p70 , TNFa , TNF-R1 , TNF-R2 , PCT LPS patient blood : 6 , 24 72 hour termination CPB . Secondary : Bleeding , need allogenic blood transfusion blood product clinical effect focus know complication cardiac surgery CPB . Design Prospective randomise clinical trial include 40 patient plan on-pump coronary artery bypass grafting ( CABG ) . n=20 trial group ( use cell saver ) n=20 control group ( cell saver ) . No patient receive postoperative autotransfusion drain blood . Sample size Estimation base comparable study . Anaesthesia surgery In accordance current guideline clinic , include prophylactic antibiotic ( cefuroxime gentamycin ) . Cell saver : Medtronic Autolog . Patient exclusion trial Patients exclude case autotransfusion blood cleanse cell saver , instance case major blood loss .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Oral write informed consent . No limit regard age ejection fraction . Offpump coronary artery bypass graft Redo CABG Current infection Antibiotic treatment Screatinin &gt; 200 micromol/L Antiinflammatory / immunomodulating treatment : Steroids , immunosuppressive stimulating agent ( NSAIDs ASA allow ) Liver disease Immune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>systemic inflammatory response syndrome</keyword>
	<keyword>coronary artery bypass grafting</keyword>
	<keyword>cell saver</keyword>
	<keyword>interleukin</keyword>
	<keyword>tumor necrosis factor alfa</keyword>
</DOC>